Mohamed Jalloh
Research Subjects
Mohamed Jalloh has a total of 594 co-authors. Here are the top co-authors by number of shared publications:
- Oumar Gaye
Urology Department of Dalal Jamm Hospital, Dakar, Senegal
7 shared publications Ben Adusei
37 Military Hospital, Accra, Ghana
6 shared publications- James Edward Mensah
Department of Surgery, Korle Bu Teaching Hospital, Accra, Ghana
6 shared publications - Joseph Lachance
Georgia Institute of Technology
6 shared publications Lamine Niang
Université Cheikh Anta Diop de Dakar, Dakar, Senegal
6 shared publications- Timothy Richard Rebbeck
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
6 shared publications
Latest Publications
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500431
Association of Family History and Polygenic Risk Scores With Prostate Cancer in Africa
PURPOSE: African ancestry and family history (FHx) of prostate cancer (CaP) are among the few established CaP risk factors. Few studies have evaluated the association of FHx of CaP with the risk of this disease in African men. METHODS: Using the Men of African Descent and Carcinoma of the Prostate (MADCaP) network, we evaluated the association of self-reported FHx of CaP in fathers and brothers in a case-control study of 2,505 prostate cancer cases and 2,222 age-matched controls ascertained from seven centers across Africa. We compared the association of FHx and a 451-SNP polygenic risk score (PRS). RESULTS: Compared with controls, CaP cases had a higher proportion of fathers and/or brothers with a history of CaP overall, as well as in men age P < .001). A CaP diagnosis in fathers was associated with an odds ratio (OR) of 3.90 (95% CI, 2.66 to 5.72), 3.13 (95% CI, 2.02 to 4.86) in brothers, and 3.41 (95% CI, 2.51 to 4.64) in fathers and/or brothers. A one-unit PRS change was associated with an OR of 1.92 (95% CI, 1.72 to 2.13). Estimates for the PRS effect did not change substantially when FHx was included in the model. CONCLUSION: FHx is a strong predictor of CaP in African men. PRS is also associated with CaP largely independently of FHx. FHx may not always be reliably reported in Africa but the magnitude of recall or reporting bias is unlikely to have negated the observed association.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500431
Association of Family History and Polygenic Risk Scores With Prostate Cancer in Africa
PURPOSE: African ancestry and family history (FHx) of prostate cancer (CaP) are among the few established CaP risk factors. Few studies have evaluated the association of FHx of CaP with the risk of this disease in African men. METHODS: Using the Men of African Descent and Carcinoma of the Prostate (MADCaP) network, we evaluated the association of self-reported FHx of CaP in fathers and brothers in a case-control study of 2,505 prostate cancer cases and 2,222 age-matched controls ascertained from seven centers across Africa. We compared the association of FHx and a 451-SNP polygenic risk score (PRS). RESULTS: Compared with controls, CaP cases had a higher proportion of fathers and/or brothers with a history of CaP overall, as well as in men age P < .001). A CaP diagnosis in fathers was associated with an odds ratio (OR) of 3.90 (95% CI, 2.66 to 5.72), 3.13 (95% CI, 2.02 to 4.86) in brothers, and 3.41 (95% CI, 2.51 to 4.64) in fathers and/or brothers. A one-unit PRS change was associated with an OR of 1.92 (95% CI, 1.72 to 2.13). Estimates for the PRS effect did not change substantially when FHx was included in the model. CONCLUSION: FHx is a strong predictor of CaP in African men. PRS is also associated with CaP largely independently of FHx. FHx may not always be reliably reported in Africa but the magnitude of recall or reporting bias is unlikely to have negated the observed association.
- Open Access
- 4 June 2025
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 6 (3) , 36
SIU-ICUD: Screening and Early Detection of Prostate Cancer
Background/Objectives: Randomised trials show that screening with prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to high rates of overdiagnosis. Today, improved diagnostic methods more selectively detect potentially lethal, high-grade prostate cancer. Methods: This is a narrative review of modern diagnostic methods, ongoing trials, national policies and knowledge gaps related to screening and early detection of prostate cancer. Results: Screening intervals can be prolonged in men with PSA values below around 1 ng/mL as these men are at very low long-term risk of prostate cancer death. Overdiagnosis can be reduced by magnetic resonance imaging (MRI) and lesion-targeted prostate biopsies. Risk calculators and ancillary biomarkers can select men for further investigation and thereby reduce resource needs. These new methods are evaluated in large, randomised screening trials. The remaining knowledge gaps include optimal PSA cut-offs, screening intervals, start and stop ages, and the long-term balance between benefits and harm. Until recently, almost no national healthcare authority recommended population-based screening for prostate cancer. Now, the European Union Council recommends an evaluation of the feasibility of organised, risk-stratified screening. This has led to several pilot projects. In some other parts of the world, such as sub-Saharan Africa and the Caribbean, such initiatives are lacking despite high prostate cancer mortality rates. Conclusions: Risk-stratified prostate cancer screening including MRI and targeted biopsy reduces overdiagnosis. Results from ongoing research are needed to optimise screening protocols and to define long-term benefits and harms. Initiatives for early detection and screening are emerging across the world but are still lacking in many countries with high prostate cancer mortality.
- 4 June 2025
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 6 (3) , 36
Open AccessSIU-ICUD: Screening and Early Detection of Prostate Cancer
Background/Objectives: Randomised trials show that screening with prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to high rates of overdiagnosis. Today, improved diagnostic methods more selectively detect potentially lethal, high-grade prostate cancer. Methods: This is a narrative review of modern diagnostic methods, ongoing trials, national policies and knowledge gaps related to screening and early detection of prostate cancer. Results: Screening intervals can be prolonged in men with PSA values below around 1 ng/mL as these men are at very low long-term risk of prostate cancer death. Overdiagnosis can be reduced by magnetic resonance imaging (MRI) and lesion-targeted prostate biopsies. Risk calculators and ancillary biomarkers can select men for further investigation and thereby reduce resource needs. These new methods are evaluated in large, randomised screening trials. The remaining knowledge gaps include optimal PSA cut-offs, screening intervals, start and stop ages, and the long-term balance between benefits and harm. Until recently, almost no national healthcare authority recommended population-based screening for prostate cancer. Now, the European Union Council recommends an evaluation of the feasibility of organised, risk-stratified screening. This has led to several pilot projects. In some other parts of the world, such as sub-Saharan Africa and the Caribbean, such initiatives are lacking despite high prostate cancer mortality rates. Conclusions: Risk-stratified prostate cancer screening including MRI and targeted biopsy reduces overdiagnosis. Results from ongoing research are needed to optimise screening protocols and to define long-term benefits and harms. Initiatives for early detection and screening are emerging across the world but are still lacking in many countries with high prostate cancer mortality.
- Open Access
- 10 February 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (2) , 334-344
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10−8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6% to 16.6% for European ancestry, 5.5% to 9.5% for African ancestry, 13.5% to 18.2% for Hispanic/Latino and 8.6% to 15.3% for Asian ancestry and decreased with increasing age. Midlife genetically adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA levels. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.
- 10 February 2025
- Published by Springer Nature in Nature Genetics
- Vol. 57 (2) , 334-344
Open AccessGenome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves prediction across ancestry groups
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10−8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6% to 16.6% for European ancestry, 5.5% to 9.5% for African ancestry, 13.5% to 18.2% for Hispanic/Latino and 8.6% to 15.3% for Asian ancestry and decreased with increasing age. Midlife genetically adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA levels. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.
- Open Access
- 16 October 2024
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 5 (5) , 320-329
Burden of Benign Prostatic Hyperplasia (BPH) in Low- and Middle-Income Countries in Sub-Saharan Africa (SSA)
Background: Benign prostatic hyperplasia (BPH) is the leading cause of lower urinary tract symptoms (LUTSs) in men, with a histological prevalence that increases significantly with age. While extensive research on BPH has been conducted in high-income countries (HICs), limited information exists regarding its burden in low- and middle-income countries (LMICs), especially in Sub-Saharan Africa (SSA). Understanding the prevalence, impact on quality of life, and management practices in these regions is crucial for developing effective healthcare policies and improving patient outcomes. Objectives: This scoping review aims to collate the existing literature on the burden of BPH in LMICs, focusing on prevalence rates, quality-of-life impact, and management practices. The goal is to provide a comprehensive overview that informs healthcare strategies in resource-constrained settings. Methods: A scoping review methodology was employed, following the framework proposed by Arksey and O’Malley. The review encompassed five stages: identifying the research question, identifying relevant studies, study selection, charting the data, and collating, summarizing, and reporting the results. A comprehensive search of electronic databases, including Google Scholar, PubMed, Scopus, and Embase, was conducted using specific search terms related to BPH and LMICs. The inclusion criteria were studies conducted in LMICs (limited to SSA); reporting on the prevalence, impact, or management of BPH; and published in English. Results: The review included studies that reported the wide-ranging prevalence rates of BPH in LMICs, highlighting significant regional variations. The impact of BPH on quality of life was profound, with many men experiencing significant bother and reduced daily functioning due to LUTSs. The management practices in these regions often differed from those in HICs, with limited access to pharmacological treatments and surgical interventions. The economic burden of BPH in LMICs was also notable, with many patients facing financial barriers to accessing effective care. Conclusions: BPH poses a significant health and economic burden in LMICs, particularly in SSA. The prevalence of the condition is high, and its impact on quality of life is substantial. There is an urgent need for improved diagnostic and management strategies tailored to the resources available in these settings. Policymakers should consider integrating BPH management into broader healthcare initiatives to enhance patient outcomes and reduce the overall burden of the disease.
- 16 October 2024
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 5 (5) , 320-329
Open AccessBurden of Benign Prostatic Hyperplasia (BPH) in Low- and Middle-Income Countries in Sub-Saharan Africa (SSA)
Background: Benign prostatic hyperplasia (BPH) is the leading cause of lower urinary tract symptoms (LUTSs) in men, with a histological prevalence that increases significantly with age. While extensive research on BPH has been conducted in high-income countries (HICs), limited information exists regarding its burden in low- and middle-income countries (LMICs), especially in Sub-Saharan Africa (SSA). Understanding the prevalence, impact on quality of life, and management practices in these regions is crucial for developing effective healthcare policies and improving patient outcomes. Objectives: This scoping review aims to collate the existing literature on the burden of BPH in LMICs, focusing on prevalence rates, quality-of-life impact, and management practices. The goal is to provide a comprehensive overview that informs healthcare strategies in resource-constrained settings. Methods: A scoping review methodology was employed, following the framework proposed by Arksey and O’Malley. The review encompassed five stages: identifying the research question, identifying relevant studies, study selection, charting the data, and collating, summarizing, and reporting the results. A comprehensive search of electronic databases, including Google Scholar, PubMed, Scopus, and Embase, was conducted using specific search terms related to BPH and LMICs. The inclusion criteria were studies conducted in LMICs (limited to SSA); reporting on the prevalence, impact, or management of BPH; and published in English. Results: The review included studies that reported the wide-ranging prevalence rates of BPH in LMICs, highlighting significant regional variations. The impact of BPH on quality of life was profound, with many men experiencing significant bother and reduced daily functioning due to LUTSs. The management practices in these regions often differed from those in HICs, with limited access to pharmacological treatments and surgical interventions. The economic burden of BPH in LMICs was also notable, with many patients facing financial barriers to accessing effective care. Conclusions: BPH poses a significant health and economic burden in LMICs, particularly in SSA. The prevalence of the condition is high, and its impact on quality of life is substantial. There is an urgent need for improved diagnostic and management strategies tailored to the resources available in these settings. Policymakers should consider integrating BPH management into broader healthcare initiatives to enhance patient outcomes and reduce the overall burden of the disease.
- 2 October 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (10) , 2093-2103
Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa
Men of African descent have the highest prostate cancer incidence and mortality rates, yet the genetic basis of prostate cancer in African men has been understudied. We used genomic data from 3,963 cases and 3,509 controls from Ghana, Nigeria, Senegal, South Africa and Uganda to infer ancestry-specific genetic architectures and fine-map disease associations. Fifteen independent associations at 8q24.21, 6q22.1 and 11q13.3 reached genome-wide significance, including four new associations. Intriguingly, multiple lead associations are private alleles, a pattern arising from recent mutations and the out-of-Africa bottleneck. These African-specific alleles contribute to haplotypes with odds ratios above 2.4. We found that the genetic architecture of prostate cancer differs across Africa, with effect size differences contributing more to this heterogeneity than allele frequency differences. Population genetic analyses reveal that African prostate cancer associations are largely governed by neutral evolution. Collectively, our findings emphasize the utility of conducting genetic studies that use diverse populations.
- 2 October 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (10) , 2093-2103
Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa
Men of African descent have the highest prostate cancer incidence and mortality rates, yet the genetic basis of prostate cancer in African men has been understudied. We used genomic data from 3,963 cases and 3,509 controls from Ghana, Nigeria, Senegal, South Africa and Uganda to infer ancestry-specific genetic architectures and fine-map disease associations. Fifteen independent associations at 8q24.21, 6q22.1 and 11q13.3 reached genome-wide significance, including four new associations. Intriguingly, multiple lead associations are private alleles, a pattern arising from recent mutations and the out-of-Africa bottleneck. These African-specific alleles contribute to haplotypes with odds ratios above 2.4. We found that the genetic architecture of prostate cancer differs across Africa, with effect size differences contributing more to this heterogeneity than allele frequency differences. Population genetic analyses reveal that African prostate cancer associations are largely governed by neutral evolution. Collectively, our findings emphasize the utility of conducting genetic studies that use diverse populations.
- 1 July 2024
- Published by Medpharm Publications in African Urology
- Vol. 4 (2) , 75-79
Contribution of the transperineal prostatic biopsy: descriptive study of the first cases at the Hôpital Général Idrissa Pouye, Dakar
- 1 July 2024
- Published by Medpharm Publications in African Urology
- Vol. 4 (2) , 75-79
Contribution of the transperineal prostatic biopsy: descriptive study of the first cases at the Hôpital Général Idrissa Pouye, Dakar
- Open Access
- 11 April 2024
- Published by Science Publishing Group in International Journal of Clinical Oncology and Cancer Research
- Vol. 9 (2) , 31-35
A Secondary Urothelial Carcinoma of the Penis Diagnosed
Aim: Penile cancer is one of the rarest urogenital cancers. Penile metastases after cystectomy are possible and seem to be associated with the existence of an extensive tumor on the surgical specimen. Case Presentation: We report here the case of old man 78 years old, with a history of Radical Cysto-Prostatectomy with Bricker type urinary diversion, indicated for a pT3N0M0R0 infiltrating urothelial carcinoma of the bladder. He had consulted 7 years post surgery for an indurated lesion of the penis with urethrorrhagia. On examination, he presented an ulcerative-necrotic lesion under the left lateral coronal area of the penis, a diffuse induration of corporal bodies from the glans to the bulb, bilateral inguinal macro lymphadenopathies. Magnetic Resonance Imaging of the penis suggested a tumor extending over the entire penis, infiltrating the corpora cavernosa and spongiosa, with invasion of the albuginea, adjacent fat and skin. In view of this picture, a total penectomy with emasculation was performed. The histology of the surgical specimen showed a poorly differentiated urothelial carcinoma with an immunohistochemical study in favor of a primary urothelial origin (GATA3+). The tumor infiltrated both corpora cavernosa and the urethra with positive margins of resection. The right inguinal lymph node dissection showed one metastatic node out of two. The left inguinal lymph node dissection showed one metastatic lymph node out of six with capsular rupture. Thoracic-abdominopelvic CT Scan showed a right inguinal adenopathy with no other lesions suggestive of secondary localization. The diagnosis of secondary urothelial carcinoma of the penis classified as pT4N2M0R1 was made and the patient underwent chemotherapy on tumor board meeting. Conclusion: Secondary cancers of the penis, although rare, can occur years after radical treatment of the primary tumor. Immuno-histochemestry was esential to differentiate from primary squamous cell carcinoma in our case.
- 11 April 2024
- Published by Science Publishing Group in International Journal of Clinical Oncology and Cancer Research
- Vol. 9 (2) , 31-35
Open AccessA Secondary Urothelial Carcinoma of the Penis Diagnosed
Aim: Penile cancer is one of the rarest urogenital cancers. Penile metastases after cystectomy are possible and seem to be associated with the existence of an extensive tumor on the surgical specimen. Case Presentation: We report here the case of old man 78 years old, with a history of Radical Cysto-Prostatectomy with Bricker type urinary diversion, indicated for a pT3N0M0R0 infiltrating urothelial carcinoma of the bladder. He had consulted 7 years post surgery for an indurated lesion of the penis with urethrorrhagia. On examination, he presented an ulcerative-necrotic lesion under the left lateral coronal area of the penis, a diffuse induration of corporal bodies from the glans to the bulb, bilateral inguinal macro lymphadenopathies. Magnetic Resonance Imaging of the penis suggested a tumor extending over the entire penis, infiltrating the corpora cavernosa and spongiosa, with invasion of the albuginea, adjacent fat and skin. In view of this picture, a total penectomy with emasculation was performed. The histology of the surgical specimen showed a poorly differentiated urothelial carcinoma with an immunohistochemical study in favor of a primary urothelial origin (GATA3+). The tumor infiltrated both corpora cavernosa and the urethra with positive margins of resection. The right inguinal lymph node dissection showed one metastatic node out of two. The left inguinal lymph node dissection showed one metastatic lymph node out of six with capsular rupture. Thoracic-abdominopelvic CT Scan showed a right inguinal adenopathy with no other lesions suggestive of secondary localization. The diagnosis of secondary urothelial carcinoma of the penis classified as pT4N2M0R1 was made and the patient underwent chemotherapy on tumor board meeting. Conclusion: Secondary cancers of the penis, although rare, can occur years after radical treatment of the primary tumor. Immuno-histochemestry was esential to differentiate from primary squamous cell carcinoma in our case.
- Top Cited Papers
- 9 November 2023
- Published by Springer Nature in Nature Genetics
- Vol. 55 (12) , 2065-2074
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry genome-wide association study of 156,319 prostate cancer cases and 788,443 controls of European, African, Asian and Hispanic men, reflecting a 57% increase in the number of non-European cases over previous prostate cancer genome-wide association studies. We identified 187 novel risk variants for prostate cancer, increasing the total number of risk variants to 451. An externally replicated multi-ancestry GRS was associated with risk that ranged from 1.8 (per standard deviation) in African ancestry men to 2.2 in European ancestry men. The GRS was associated with a greater risk of aggressive versus non-aggressive disease in men of African ancestry (P = 0.03). Our study presents novel prostate cancer susceptibility loci and a GRS with effective risk stratification across ancestry groups.
- 9 November 2023
- Published by Springer Nature in Nature Genetics
- Vol. 55 (12) , 2065-2074
Top Cited PapersCharacterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
The transferability and clinical value of genetic risk scores (GRSs) across populations remain limited due to an imbalance in genetic studies across ancestrally diverse populations. Here we conducted a multi-ancestry genome-wide association study of 156,319 prostate cancer cases and 788,443 controls of European, African, Asian and Hispanic men, reflecting a 57% increase in the number of non-European cases over previous prostate cancer genome-wide association studies. We identified 187 novel risk variants for prostate cancer, increasing the total number of risk variants to 451. An externally replicated multi-ancestry GRS was associated with risk that ranged from 1.8 (per standard deviation) in African ancestry men to 2.2 in European ancestry men. The GRS was associated with a greater risk of aggressive versus non-aggressive disease in men of African ancestry (P = 0.03). Our study presents novel prostate cancer susceptibility loci and a GRS with effective risk stratification across ancestry groups.
- Open Access
- 12 October 2023
- Published by Springer Nature in Research Square
Heterogeneous genetic architectures and evolutionary genomics of prostate cancer in Sub-Saharan Africa
Men of African descent have the highest prostate cancer (CaP) incidence and mortality rates, yet the genetic basis of CaP in African men has been understudied. We used genomic data from 3,963 CaP cases and 3,509 controls recruited in Ghana, Nigeria, Senegal, South Africa, and Uganda, to infer ancestry-specific genetic architectures and fine-mapped disease associations. Fifteen independent associations at 8q24.21, 6q22.1, and 11q13.3 reached genome-wide significance, including four novel associations. Intriguingly, multiple lead SNPs are private alleles, a pattern arising from recent mutations and the out-of-Africa bottleneck. These African-specific alleles contribute to haplotypes with odds ratios above 2.4. We found that the genetic architecture of CaP differs across Africa, with effect size differences contributing more to this heterogeneity than allele frequency differences. Population genetic analyses reveal that African CaP associations are largely governed by neutral evolution. Collectively, our findings emphasize the utility of conducting genetic studies that use diverse populations.
- 12 October 2023
- Published by Springer Nature in Research Square
Open AccessHeterogeneous genetic architectures and evolutionary genomics of prostate cancer in Sub-Saharan Africa
Men of African descent have the highest prostate cancer (CaP) incidence and mortality rates, yet the genetic basis of CaP in African men has been understudied. We used genomic data from 3,963 CaP cases and 3,509 controls recruited in Ghana, Nigeria, Senegal, South Africa, and Uganda, to infer ancestry-specific genetic architectures and fine-mapped disease associations. Fifteen independent associations at 8q24.21, 6q22.1, and 11q13.3 reached genome-wide significance, including four novel associations. Intriguingly, multiple lead SNPs are private alleles, a pattern arising from recent mutations and the out-of-Africa bottleneck. These African-specific alleles contribute to haplotypes with odds ratios above 2.4. We found that the genetic architecture of CaP differs across Africa, with effect size differences contributing more to this heterogeneity than allele frequency differences. Population genetic analyses reveal that African CaP associations are largely governed by neutral evolution. Collectively, our findings emphasize the utility of conducting genetic studies that use diverse populations.
- 1 October 2023
- Published by Medpharm Publications in African Urology
- Vol. 3 (3) , 175-178
La fracture de verge : résultats fonctionnels du traitement chirurgical à l’Hôpital Général Idrissa Pouye de Dakar
- 1 October 2023
- Published by Medpharm Publications in African Urology
- Vol. 3 (3) , 175-178
La fracture de verge : résultats fonctionnels du traitement chirurgical à l’Hôpital Général Idrissa Pouye de Dakar